IP Update
 

AstraZeneca succeeds in omeprazole patent infringement profits case

by Urszula Wojtyra

The Federal Court has issued its Public Judgment and Reasons concerning the financial compensation to be paid to AstraZeneca as a result of Apotex’s infringement of the omeprazole formulation patent (AstraZeneca’s LOSEC) in AstraZeneca v Apotex Inc 2017 FC 726.

AstraZeneca elected an accounting of Apotex’s profits after Justice Barnes found the omeprazole formulation patent valid and infringed during the liability phase (reported here). The parties had substantially settled many of the quantification issues relating to Apotex’s profits, leaving four issues for the Court to decide following a 28-day trial – all of which were decided in AstraZeneca’s favour.

AstraZeneca was successfully represented by a trial team from Smart & Biggar, including Nancy Pei, Mark Biernacki, J. Sheldon Hamilton, Urszula Wojtyra, Abigail Smith, Paul Jorgenson and Brandon Heard.

To learn more, click here »

Connect with us:

    Follow @smartbiggar  Follow Smart & Biggar

Smart & Biggar named the 2017 “Canadian IP Litigation Firm of the Year” by Benchmark Canada for the third consecutive year.

Read more »

Smart & Biggar was awarded the Milestone Case of the Year for North America and named Canadian Trademark Contentious Firm of the Year by Managing Intellectual Property.

Read more »

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

Smart & Biggar/Fetherstonhaugh

Smart & Biggar/Fetherstonhaugh

If you do not wish to receive future mailings of this kind (seminar invitations, greeting cards, notification of legal developments), please access the Manage Your Subscription link below to unsubscribe and to manage your settings.

smart-biggar.ca